The new antidiabetic agents in the firing line.... safety reasons or witch hunt?;Los nuevos antidiabéticos en el punto de mira... ¿razones de seguridad o caza de brujas?

Endocrinologia y Nutricion

Volumn 59, Issue 1, 2012, Pages 1-8

  Nicolau Ramis, Joana ^a   Masmiquel Comas, Lluís ^a  

^a HOSPITAL SON LLÀTZER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT;

ARTICLE; DRUG SAFETY;

ANIMALS; BREAST NEOPLASMS; CALCITONIN; CARCINOMA, MEDULLARY; CLINICAL TRIALS AS TOPIC; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DISEASE SUSCEPTIBILITY; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INFECTION; PANCREATITIS; PHARMACOVIGILANCE; PYRAZINES; RISK ASSESSMENT; SAFETY-BASED DRUG WITHDRAWALS; SPECIES SPECIFICITY; THIAZOLIDINEDIONES; THYROID NEOPLASMS; TRIAZOLES; URINARY BLADDER NEOPLASMS;

EID: 84856211124     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2011.11.002     Document Type: Article

References (56)

1. US Food and Drug Administration. FDA significantly restricts access to the diabetes drug Avandia. Disponible en: (consultado 27 Sep 2010). http://www.fda.gov/newsevents/newsroom/pressannouncements/UCM226975htm.
2. European Medicines Agency. European Medicines Agency recommends suspension of Avandia, Avandamet, Avaglim. Disponible en: (consultado 27 Sep 2010). http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/news_and_events/news/2010/09/news_detail_001119.jsp%26murl=menus/news_and_events/news_and_events.jsp%26miid=WC0b01ac058004d5cl%26jsenabled=true.
3. Nissen S.E., Wolski K. Effect of rosiglitazona on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
4. World Health Organization. Diabetes Fact Sheet. Disponible en: (Consultado 29 Dic 2009). http://www.who.int/mediacentre/factsheets/fs312/en/index.html.
5. US Food and Drug Administration. Guidance for Industry. Diabetes Mellitus-Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. [consultado 26/4/2010]. Disponible en: http://www.fda.gov/downloads/Drugs/Guidance%20ComplianceRegulatoryInformation/Guidances/ucm071627.pdf.
6. Bloomgarden Z. The Avandia debate: An unhappy conclusion. J Diab 2010, 2:221-222.
7. Dormandy J., Charbonnel B., Eckland D., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005, 366:1279-1289.
8. Betteridge J. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. Fund Clin Pharmacol 2009, 23:675-679.
9. Shen D., Deng C., Zhang M. Peroxisome proliferator-activated receptor gamma agonists inhibit the proliferation and invasion of human colon cancer cells. Postgrad Med J 2007, 83:414-419.
10. Ferrara A., Lewis J., Quesenberry C.P., Peng T., Strom B.L., Van Den Eeden S.K., et al. Cohort Study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 2011, 34:923-929.
11. Takeda Pharmaceuticals America, Inc. Actos (Pioglitazone Hydrochloride) Tablets: Full Prescribing Information. 2009; Disponible en: (Consultado 26 Aug 2010). http://www.actos.com/actospro/home.aspx.
12. Dominick M.A., White M.R., Sanderson T.P., Van Vleet T., Cohen S.M., Arnold L.E., et al. Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: evidence for urolithiasis as the inciting event in the mode of action. Toxicol Pathol 2006, 34:903-910.
13. Koro C., Barrett S., Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agets. Pharmacoepidemiol drug Saf 2007, 16:485-492.
14. Govindajaran R., Ratnasinghe L., Simmons D.L. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007, 12:1476-1481.
15. Lewis J., Ferrara A., Peng T., Hedderson M., Bilker W., Quesenberry C.H., et al. Risk of bladder cancer among diabetic patients treated with pioglitazone. Diabetes Care 2011, 34:916-922.
16. Risque de cancer de la vessie chez les personnes diabétiques traitées par pioglitazone en France: une étude de cohorte sur les données du SNIIRAM et du PMSI. [consultado 7/6/2011]. Disponible en: http://www.afssaps.fr/var/afssaps_site/storage/original/application/b42a6bf9a1b63c3dbec7388d3914687b.pdf.
17. Piccinni C., Motola D., Marchesini G., Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011, 34:1369-1371.
18. US Food and Drug Administration. Actos (pioglitazone): ongoing safety review. Potential increased risk of bladder cancer. Disponible en: (consultado15 Jun 2011). http://www.fda.gov/Drugs/DrugSafety/UCM259150.htm.
19. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Pioglitazona: evaluación europea de su posible asociación con el cáncer de vejiga. [consultado 28/6/2011]. Disponible en: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2011/NI-MUH_10-2011.htm.
20. Jones D. Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor. Nat Rev Drug Discov 2011, 10:645-646.
21. Victoza® (Package insert). Princeton, NJ: Novo Nordisk, Inc; 2010. Disponiible en: (consultado 19 Mar 2010). http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/0223411bl.pdf.
22. Montanya E., Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther 2009, 31:2472-2488.
23. Peters K. Liraglutide for the treatment of type 2 diabetes: a clinical update. Am J Ther 2011, [Epub ahead of print].
24. Schmidt W.E. Early clinical studies with liraglutide. Int J Clin Pract 2010, 64:12-20.
25. Costante G., Durante C., Francis Z., Schlumberger M., Filetti S. Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. Nat Clin Pract Endocrinol Metab 2009, 5:35-44.
26. Bjerre Knudsen L., Madsen L.W., Andersen S., Almholt K., De Boer A.S., Drucker D.J., et al. Glucagon-like-peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010, 151:1473-1486.
27. Yamada C., Yamada Y., Tsukiyama K. The murine glucagon-like-peptide-1 receptor is essential for control of bone resorption. Endocrinology 2008, 149:574-579.
28. Bloomgarden Z. Liraglutide and calcitonin. J Diab 2010, 2:223-224.
29. Guyétant S., Bléchet C., Saint-André J.P. C-cell hyperplasia. Ann Endocrinol (Paris) 2006, 67:190-197.
30. Hegedüs L., Moses A.C., Zdravkovic M., Thi T.L., Daniels G.H. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5,000 subjects with type 2 diabetes or nondiabetic obese subjects treated with human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 2011, 853-860.
31. Parks M., Rosebraugh C. Weighing risks and benefits of liraglutide, The FDA's review of a new antidiabetic therapy. N Engl J Med 2010, 362:774-775.
32. Drzewoski J., Drozdowska A., Sliwinska A. Do we have enough data to confirm the link between antidiabetic drug use and cancer development?. Pol Arch Med Wewn 2011, 121:81-87.
33. Smith U., Gale E.M. Cancer and diabetes: are we ready for prime time?. Diabetologia 2010, 53:1541-1544.
34. Johnson J.A., Bowker S.L. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 2011, 54:25-31.
35. Decensi A., Puntoni M., Goodwin P. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010, 3:1451-1461.
36. Landman G.W., Kleefstra N., van Hateren K.J.J. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010, 33:322-326.
37. Bowker S.L., Majumdar S.R., Veugelers P., Johnson J.A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006, 29:254-258.
38. Monami M., Balzi D., Lamanna C. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 2007, 23:479-484.
39. Balani A.R., Grendell J.H. Drug-induced pancreatitis. Drug Saf 2008, 31:823-837.
40. Noel R.A., Braun D.K., Patterson R.E., Bloomgren G.L. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes. Diabetes Care 2009, 32:834-838.
41. Olansky L. Do incretin-based therapies cause acute pancreatitis?. J Diabetes Sci Technol 2010, 4:228-229.
42. Denker P.S., Dimarco P.E. Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care 2006, 29:471.
43. Dore D.D., Bloomgren G.L., Wenten M., Hoffman C., Clifford C.R., Quinn S.G., et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011 Jun, 13:559-566.
44. Garg R., Chen W., Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010 Nov, 33:2349-2354.
45. Elashoff M., Matveyenko A.V., Gier B., Elashoff R., Butler P.C. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011, 141:150-156.
46. ®). Dtsch Arztebl 2011, 108:A-1080. Arzneimittelkommission der Deutschen ärzrteschaft (Drug Commission of the German Medical Association).
47. Nachnani J.S., Bulchandani D.G., Nookala A., Herndon B., Molteni A., Pandya P., et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2010, 53:153-159.
48. Butler P.C., Matveyenko A.V., Dry S., Bhushan A., Elashoff R. Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?. Diabetologia 2010, 53:1-6.
49. Engel S.S., Williams-Herman D.E., Golm G.T., Clay R.J., Machotka S.V., Kaufman K.D., et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010, 64:984-990.
50. Matveyenko A.V., Dry S., Cox H.I., Moshtaghian A., Gurlo T., Galasso R., et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 2009, 58:1604-1615.
51. Ligueros-Saylan M., Foley J.E., Schweizer A., Couturier A., Kothny W. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab 2010, 12:495-509.
52. Girgis C.M., Champion B.L. Vildagliptin-induced acute pancreatitis. Endocr Pract 2011, 17:e48-e50.
53. Willemen M.J., Mantel-Teeuwisse A.K., Straus S.M., Meyboom R.H., Egberts T.C., Leufkens H.G. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care 2011, 34:369-374.
54. White P.C., Chamberlain-Shea H., de la Morena M.T. J Diabetes Complications, Sitagliptin treatment of patients with type 2 diabetes does not affect CD4+ T-cell activation 2010, 24:209-213.
55. Williams-Herman D., Engel S.S., Round E. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010, 10:7.
56. Us Food and Drug Administration. Running Clinical Trials. [consultado 5/4/2011]. Disponible en:. http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/default.htm.